S&P 500   4,571.62 (-1.80%)
DOW   34,483.08 (-1.86%)
QQQ   392.82 (-1.72%)
AAPL   163.39 (+1.97%)
MSFT   330.46 (-1.83%)
FB   326.19 (-3.50%)
GOOGL   2,850.01 (-2.08%)
AMZN   3,506.66 (-1.54%)
TSLA   1,129.91 (-0.62%)
NVDA   321.10 (-3.79%)
BABA   126.74 (-3.70%)
NIO   38.83 (-4.03%)
CGC   10.39 (-6.06%)
AMD   156.35 (-3.43%)
GE   94.51 (-3.95%)
MU   84.46 (-1.95%)
T   22.59 (-5.44%)
F   19.12 (-2.80%)
DIS   143.98 (-2.59%)
ACB   6.20 (-3.73%)
AMC   33.79 (-8.28%)
PFE   54.17 (+3.38%)
BA   194.55 (-1.99%)
S&P 500   4,571.62 (-1.80%)
DOW   34,483.08 (-1.86%)
QQQ   392.82 (-1.72%)
AAPL   163.39 (+1.97%)
MSFT   330.46 (-1.83%)
FB   326.19 (-3.50%)
GOOGL   2,850.01 (-2.08%)
AMZN   3,506.66 (-1.54%)
TSLA   1,129.91 (-0.62%)
NVDA   321.10 (-3.79%)
BABA   126.74 (-3.70%)
NIO   38.83 (-4.03%)
CGC   10.39 (-6.06%)
AMD   156.35 (-3.43%)
GE   94.51 (-3.95%)
MU   84.46 (-1.95%)
T   22.59 (-5.44%)
F   19.12 (-2.80%)
DIS   143.98 (-2.59%)
ACB   6.20 (-3.73%)
AMC   33.79 (-8.28%)
PFE   54.17 (+3.38%)
BA   194.55 (-1.99%)
S&P 500   4,571.62 (-1.80%)
DOW   34,483.08 (-1.86%)
QQQ   392.82 (-1.72%)
AAPL   163.39 (+1.97%)
MSFT   330.46 (-1.83%)
FB   326.19 (-3.50%)
GOOGL   2,850.01 (-2.08%)
AMZN   3,506.66 (-1.54%)
TSLA   1,129.91 (-0.62%)
NVDA   321.10 (-3.79%)
BABA   126.74 (-3.70%)
NIO   38.83 (-4.03%)
CGC   10.39 (-6.06%)
AMD   156.35 (-3.43%)
GE   94.51 (-3.95%)
MU   84.46 (-1.95%)
T   22.59 (-5.44%)
F   19.12 (-2.80%)
DIS   143.98 (-2.59%)
ACB   6.20 (-3.73%)
AMC   33.79 (-8.28%)
PFE   54.17 (+3.38%)
BA   194.55 (-1.99%)
S&P 500   4,571.62 (-1.80%)
DOW   34,483.08 (-1.86%)
QQQ   392.82 (-1.72%)
AAPL   163.39 (+1.97%)
MSFT   330.46 (-1.83%)
FB   326.19 (-3.50%)
GOOGL   2,850.01 (-2.08%)
AMZN   3,506.66 (-1.54%)
TSLA   1,129.91 (-0.62%)
NVDA   321.10 (-3.79%)
BABA   126.74 (-3.70%)
NIO   38.83 (-4.03%)
CGC   10.39 (-6.06%)
AMD   156.35 (-3.43%)
GE   94.51 (-3.95%)
MU   84.46 (-1.95%)
T   22.59 (-5.44%)
F   19.12 (-2.80%)
DIS   143.98 (-2.59%)
ACB   6.20 (-3.73%)
AMC   33.79 (-8.28%)
PFE   54.17 (+3.38%)
BA   194.55 (-1.99%)
OTCMKTS:BCYP

Big Cypress Acquisition Stock Competitors

$8.44
-2.01 (-19.23%)
(As of 10/22/2021)
Add
Compare
Today's Range
$8.21
$12.90
50-Day Range
$8.44
$10.47
52-Week Range
$8.21
$12.90
Volume
15.34 million shs
Average Volume
160,982 shs
Market Capitalization
$124.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Big Cypress Acquisition (OTCMKTS:BCYP) Vs. AURA, IKNA, ATHA, TSHA, SABS, AERI, AUTL, CRIS, MOLN, and PSTX

Should you be buying Big Cypress Acquisition stock or one of its competitors? The main competitors of Big Cypress Acquisition include Aura Biosciences (AURA), Ikena Oncology (IKNA), Athira Pharma (ATHA), Taysha Gene Therapies (TSHA), SAB Biotherapeutics (SABS), Aerie Pharmaceuticals (AERI), Autolus Therapeutics (AUTL), Curis (CRIS), Molecular Partners (MOLN), and Poseida Therapeutics (PSTX). These companies are all part of the "biological products, except diagnostic" industry.

Big Cypress Acquisition vs.

Ikena Oncology (NASDAQ:IKNA) and Big Cypress Acquisition (OTCMKTS:BCYP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.

Ikena Oncology presently has a consensus price target of $27.00, indicating a potential upside of 99.56%. Big Cypress Acquisition has a consensus price target of $17.25, indicating a potential upside of 104.38%. Given Big Cypress Acquisition's higher possible upside, analysts plainly believe Big Cypress Acquisition is more favorable than Ikena Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ikena Oncology
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Big Cypress Acquisition
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Big Cypress Acquisition received 48 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 61.29% of users gave Big Cypress Acquisition an outperform vote while only 56.25% of users gave Ikena Oncology an outperform vote.

CompanyUnderperformOutperform
Ikena OncologyOutperform Votes
9
56.25%
Underperform Votes
7
43.75%
Big Cypress AcquisitionOutperform Votes
57
61.29%
Underperform Votes
36
38.71%

In the previous week, Ikena Oncology had 2 more articles in the media than Big Cypress Acquisition. MarketBeat recorded 2 mentions for Ikena Oncology and 0 mentions for Big Cypress Acquisition. Ikena Oncology's average media sentiment score of 0.00 equaled Big Cypress Acquisition's average media sentiment score.

Company Overall Sentiment
Ikena Oncology Neutral
Big Cypress Acquisition Neutral

56.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 60.2% of Big Cypress Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Ikena Oncology N/A N/A N/A
Big Cypress Acquisition N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ikena OncologyN/AN/AN/AN/AN/A
Big Cypress AcquisitionN/AN/A-$10 thousandN/AN/A

Summary

Big Cypress Acquisition beats Ikena Oncology on 4 of the 6 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Big Cypress Acquisition (OTCMKTS:BCYP) vs. Its Competitors

TypeBig Cypress AcquisitionBiological Products IndustryMedical SectorOTCMKTS Exchange
Market Cap$124.84M$3.91B$4.93B$7.63B
Dividend YieldN/A2.14%2.04%13.76%
P/E RatioN/A7.7319.362.24
Price / SalesN/A2,970.002,530.29160.55
Price / CashN/A105.5541.4327.51
Price / BookN/A6.099.535.52
Net Income-$10K$2.48M$95.31M$411.24M
7 Day PerformanceN/A-1.14%111.05%58.83%
1 Month PerformanceN/A-10.10%106.60%122.65%
1 Year PerformanceN/A3.44%160.73%111.61%

Big Cypress Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AURA
Aura Biosciences
1.825 of 5 stars
$17.09
-3.9%
$37.67
-120.4%
N/A$499.20MN/A0.00N/AGap Up
IKNA
Ikena Oncology
1.7381 of 5 stars
$13.53
-6.7%
$27.00
-99.6%
N/A$485.86MN/A0.0033
ATHA
Athira Pharma
2.1064 of 5 stars
$12.97
-4.7%
$51.00
-293.2%
-43.4%$484.43MN/A-10.0521Short Interest ↑
TSHA
Taysha Gene Therapies
2.5333 of 5 stars
$12.21
-2.6%
$46.45
-280.5%
-41.5%$469.77MN/A0.0038Positive News
SABS
SAB Biotherapeutics
2.0333 of 5 stars
$10.75
-4.9%
$20.00
-86.0%
N/A$467.36MN/A0.00N/AGap Up
AERI
Aerie Pharmaceuticals
1.9531 of 5 stars
$9.79
-2.2%
$23.66
-141.7%
-26.4%$463.65M$83.14M-2.71365Short Interest ↓
AUTL
Autolus Therapeutics
1.5464 of 5 stars
$6.15
-0.7%
$14.67
-138.5%
-36.4%$448.46M$1.72M-2.692,020Short Interest ↑
CRIS
Curis
1.9398 of 5 stars
$4.76
-1.7%
$19.80
-316.0%
+236.1%$436.06M$10.84M-10.3528
MOLN
Molecular Partners
1.805 of 5 stars
$13.50
-13.1%
$26.51
-96.3%
N/A$435.78M$9.97M0.00152Short Interest ↑
News Coverage
Gap Up
PSTX
Poseida Therapeutics
2.4664 of 5 stars
$6.84
-0.7%
$29.50
-331.3%
-40.6%$427.54MN/A-2.61206Insider Buying
Short Interest ↓
Positive News
Gap Up
CVM
CEL-SCI
1.1782 of 5 stars
$9.84
-0.3%
N/AN/A$423.42M$560K-11.182,020
CRTX
Cortexyme
2.6481 of 5 stars
$13.51
-8.0%
$38.50
-185.0%
-74.8%$403.68MN/A-4.6038
INKT
MiNK Therapeutics
1.7 of 5 stars
$12.28
-8.1%
$26.67
-117.2%
N/A$400.21MN/A0.00N/A
IPHA
Innate Pharma
1.6248 of 5 stars
$4.97
-0.4%
$11.13
-123.8%
-10.3%$394.27M$80.47M0.00244Short Interest ↑
Gap Up
JNCE
Jounce Therapeutics
2.1331 of 5 stars
$7.66
-2.9%
$15.67
-104.5%
+8.4%$392.50M$62.34M-19.64128Short Interest ↓
AMAM
Ambrx Biopharma
1.7 of 5 stars
$10.29
-0.9%
$33.43
-224.9%
N/A$387.62M$13.67M0.0070
CLLS
Cellectis
1.9281 of 5 stars
$8.51
-1.6%
$24.33
-185.9%
-65.4%$386.95M$82.46M-2.90340Analyst Report
Gap Up
IPHYF
Innate Pharma
0.9598 of 5 stars
$5.02
-4.0%
N/A-7.9%$378.81M$80.47M0.00244Short Interest ↓
News Coverage
Gap Up
LCTX
Lineage Cell Therapeutics
2.1864 of 5 stars
$2.24
-10.7%
$6.00
-167.9%
N/A$377.57M$1.83M-28.0052
PASG
Passage Bio
2.4792 of 5 stars
$6.94
-2.7%
$30.57
-340.5%
-63.5%$375.50MN/A-2.0574
SQZ
SQZ Biotechnologies
1.3333 of 5 stars
$11.98
-0.2%
N/A-61.6%$336.24M$21M0.0098Gap Up
DBVT
DBV Technologies
1.6781 of 5 stars
$2.95
-4.1%
$8.67
-193.8%
+20.4%$324.56M$11.28M0.00142Short Interest ↑
Gap Down
ABOS
Acumen Pharmaceuticals
1.4665 of 5 stars
$7.85
-3.4%
$25.00
-218.5%
N/A$317.69M$1.44M0.002,021
CABA
Cabaletta Bio
2.1064 of 5 stars
$11.05
-3.7%
$23.25
-110.4%
-23.8%$313.05MN/A-6.4634Short Interest ↑
Negative News
JSPR
Jasper Therapeutics
1.825 of 5 stars
$8.10
-3.2%
$18.33
-126.3%
N/A$306.59MN/A0.003Gap Up
CGEN
Compugen
1.7731 of 5 stars
$4.43
-0.9%
$17.67
-298.8%
-65.6%$303.10M$2M-11.0745
OPT
Opthea
1 of 5 stars
$6.84
-3.7%
N/A-48.2%$300.27M$70K0.00N/A
CADL
Candel Therapeutics
1.7 of 5 stars
$10.15
-1.0%
$16.00
-57.6%
N/A$291.20MN/A0.002,021Short Interest ↓
Gap Up
ADMA
ADMA Biologics
2.1783 of 5 stars
$1.40
-3.9%
$5.70
-308.6%
-23.7%$273.16M$42.22M-2.18407
CDAK
Codiak BioSciences
2.0648 of 5 stars
$12.19
-2.8%
$31.00
-154.3%
+30.4%$272.69M$2.91M-3.38105Gap Up
OYST
Oyster Point Pharma
2.1798 of 5 stars
$10.29
-0.2%
$23.00
-123.5%
-52.0%$269.23MN/A-3.3062Positive News
SURF
Surface Oncology
2.2314 of 5 stars
$5.67
-1.1%
$16.00
-182.2%
-27.1%$261.59M$126.16M18.2951Short Interest ↓
ENVI
Environmental Impact Acquisition
1.2664 of 5 stars
$9.98
-0.1%
N/AN/A$258.28MN/A0.00N/AShort Interest ↓
FUSN
Fusion Pharmaceuticals
2.2431 of 5 stars
$5.89
-1.4%
$18.00
-205.6%
-51.8%$253.68MN/A-3.2461
OTLK
Outlook Therapeutics
1.7581 of 5 stars
$1.43
-0.7%
$6.00
-319.6%
+17.1%$250.74M$8.15M0.008
LIFE
aTyr Pharma
2.4198 of 5 stars
$8.08
-2.1%
$18.00
-122.8%
+122.8%$224.54M$10.45M-3.9642
INMB
INmune Bio
2.2 of 5 stars
$12.49
-0.4%
$37.00
-196.2%
+40.7%$222.82M$10K-8.065
BDTX
Black Diamond Therapeutics
1.9381 of 5 stars
$6.00
-1.7%
$33.80
-463.3%
-82.3%$217.38MN/A-1.7773
CRDF
Cardiff Oncology
2.3667 of 5 stars
$5.34
-1.1%
$25.00
-368.2%
-75.4%$211.20M$370K-7.9712
EIGR
Eiger BioPharmaceuticals
2.1448 of 5 stars
$6.00
-2.8%
$31.33
-422.2%
-32.9%$203.88MN/A-6.3228
ACHL
Achilles Therapeutics
1.9517 of 5 stars
$4.94
-0.0%
$20.80
-321.1%
N/A$200.56MN/A0.00153Short Interest ↑
Negative News
TCRR
TCR2 Therapeutics
2.5781 of 5 stars
$5.10
-0.2%
$28.20
-452.9%
-81.4%$194.92MN/A-2.07118
APTO
Aptose Biosciences
2.2998 of 5 stars
$2.19
-0.5%
$11.00
-402.3%
-65.3%$194.80MN/A-3.4831Options Volume
News Coverage
HARP
Harpoon Therapeutics
2.2322 of 5 stars
$5.82
-2.9%
$28.17
-384.0%
-59.6%$190.61M$17.44M-1.7078
SLDB
Solid Biosciences
2.3648 of 5 stars
$1.70
-7.1%
$10.17
-498.0%
-42.8%$187.50MN/A-2.0570
TCRX
Tscan Therapeutics
2.1181 of 5 stars
$7.80
-1.5%
$21.67
-177.8%
N/A$185.39M$1.09M0.0061Short Interest ↑
CGTX
Cognition Therapeutics
2.1762 of 5 stars
$8.22
-0.6%
$24.50
-198.1%
N/A$181.17MN/A0.002,021
ADVM
Adverum Biotechnologies
2.3431 of 5 stars
$1.81
-3.6%
$6.43
-256.2%
-86.7%$177.16M$250K-1.19167Analyst Upgrade
Short Interest ↓
AVRO
AVROBIO
2.1523 of 5 stars
$3.86
-2.8%
$21.13
-447.3%
-71.7%$168.49MN/A-1.34121
ORTX
Orchard Therapeutics
2.0598 of 5 stars
$1.33
-2.3%
$12.75
-858.6%
-72.2%$166.91M$2.60M-1.082,020
This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.